DBV Technologies SA - American (DBV1) Stock Price & Analysis
DBV1 Stock Chart & Stats
- Day’s Range
- EUR 8.75 - EUR 8.75
- 52-Week Range
- EUR 7.60 - EUR 24.40
- Previous Close
- EUR 9.10
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 534.36M
- Enterprise Value
- EUR 790.44M
- Total Cash (Recent Filing)
- EUR 165.70M
- Total Debt (Recent Filing)
- EUR 22.20M
- Price to Earnings (P/E)
- ―
- Beta
- -0.40
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.2
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Advancement
The completed BLA submission advances VIASKIN toward potential commercialization and represents a concrete regulatory milestone. If the application progresses successfully, DBV could transition from a development-stage company toward recurring product revenue and broader commercial validation.
Low Leverage
Low leverage provides a relative solvency advantage while DBV remains in development. Modest debt reduces mandatory financing pressure from creditors and leaves greater flexibility to direct capital toward clinical, regulatory, and commercial activities during the product launch period.
Commercial Readiness
Investment in sales, market access, medical affairs, and payer engagement indicates preparation for a potential commercial launch rather than purely early-stage research. This infrastructure could support adoption and market access if regulatory approval is obtained on the planned timeline.
Bears Say
No Commercial Revenue
The absence of recurring commercial revenue leaves DBV dependent on capital markets and future regulatory success to support its cost base. Persistent and widening operating losses also show that current activities are not yet self-funding, increasing execution pressure before commercialization.
Severe Cash Burn And Funding Risk
Large cash outflows and the stated need for additional capital create a durable funding risk over the next several quarters. New financing could dilute existing holders or constrain operations, while weaker access to capital could delay clinical, regulatory, or launch plans.
Manufacturing Execution Dependency
Reliance on a manufacturing site undergoing FDA remediation makes approval and launch timing dependent on quality-system execution outside DBV's direct control. Delays in remediation or reinspection could disrupt the regulatory path and postpone the company's transition to commercial operations.
DBV Technologies SA - American News
DBV1 FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
What is DBV Technologies SA - American’s market cap?
When is DBV Technologies SA - American’s upcoming earnings report date?
How were DBV Technologies SA - American’s earnings last quarter?
Is DBV Technologies SA - American overvalued?
Does DBV Technologies SA - American pay dividends?
What is DBV Technologies SA - American’s EPS estimate?
How many shares outstanding does DBV Technologies SA - American have?
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
Which hedge fund is a major shareholder of DBV Technologies SA - American?
What is the TipRanks Smart Score and how is it calculated?
DBV Technologies SA - American Stock Smart Score
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Tassé
- Employees
- 125
- Website
- www.dbv-technologies.com
- Address
- BAtiment IRO, Châtillon, 92320, FR
DBV Technologies SA - American (DBV1) Earnings & Revenues
DBV1 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, centered on the completed 4-through-7 BLA submission, cash funding into the third quarter of 2027, progress toward commercial readiness, FDA engagement and continued advancement of the toddler program. However, the company still faces significant execution and regulatory dependencies, including Fareva's unresolved Warning Letter remediation, an unscheduled FDA reinspection, pending Priority Review decisions, uncertainty around the toddler BLA process and higher operating expenses.
View all DE:DBV1 earnings summariesDBV1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 4 | 9 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 6 | 0 | 6 |